title: Chronic myeloid leukemia--from the National to the European Registry--limited experience of a single center.
abstract: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder in which the diagnosis is confirmed by detection of a genetic marker: Philadelphia (Ph) chromosome in almost 90% of cases. Some of Ph1 negative patients, nevertheless, test positive for the abnormal gene, or the abnormal protein associated with this chromosome, when more sensitive studies, such as PCR or FISH are used and nowadays the diagnosis of CML is based, not only on cytogenetic, but also on molecular analysis. The better understanding of the CML biology provided by the latest researches requires a deeper knowledge about the epidemiologic data in each geographic area, so the compiling of a National and/or European Registry for CML patients, that represents one of the aims of this study, became a stringent matter in our days; it can offer valuable data concerning the real incidence of this disease in Romania and can provide the basics for establishing long-term budgetary strategies.
authors.affiliation: Department of Hematology, Emergency University Hospital Bucharest, "Carol Davila" University of Medicine and Pharmacy Bucharest-UMCFD, Romania. anamariavladareanu@yahoo.com
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Vlădăreanu
authors.forename: Irina
authors.initials: I
authors.lastname: Voican
authors.forename: H
authors.initials: H
authors.lastname: Bumbea
authors.forename: Daniela
authors.initials: D
authors.lastname: Vasile
authors.forename: Sânziana
authors.initials: S
authors.lastname: Radesi
authors.forename: D
authors.initials: D
authors.lastname: Coriu
authors.forename: Adriana
authors.initials: A
authors.lastname: Coliţa
authors.forename: Rodica
authors.initials: R
authors.lastname: Tălmaci
authors.forename: Anca
authors.initials: A
authors.lastname: Ilea
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015331:Cohort Studies; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012042:Registries; D012189:Retrospective Studies; D012383:Romania / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate